The headlines may have faded, but the Nitrosamine contamination saga continues. With all European Medicines Agency Marketing Authorization Holders (MAH) now obligated to evaluate the risks of their products containing chemically synthesized APIs, choosing a partner you can trust has never been more important.

‍

‍

Here at QUINTA-ANALYTICA we have developed versatile proprietary ULPC/MS/MS methods for quantitative determination of Nitrosamines under full #GMP conditions, and with the capability of reaching LOQ down to 20 ppb. Our dedicated and cross-functional Nitrosamine team is perfectly placed to meet your needs and secure delivery of test results accurately, professionally, and within the agreed time-frame.

Read more about the types of Nitrosamines and matrixes that our testing has already been proven on, and learn more about our testing processes on our webpage devoted to Nitrosamines.

Additional News

  • 22 června 2023

    Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

    EvidentIQ partners with Quinta-Analytica to enhance Phase 1 study efficiency

  • 15 června 2023

    Novavax & Conscio: Behind the Scenes of Vaccine Development

    Discover how the Conscio Group and renowned vaccine manufacturer Novavax collaborate behind the scenes to ensure quality and efficiency in vaccine production.

  • 8 června 2023

    Clinical Tips – Drug Interactions in Advanced Clinical Trial Design

    Drug interactions play a key role in the design of clinical trials. Learn how we investigate such interactions when conducting pharmacokinetic/bioequivalence studies and while offering end-to-end support throughout the process.

ALL POSTS